Status:
COMPLETED
Extracellular Matrix Marker of Arrhythmia Risk (EMMA)
Lead Sponsor:
Thomas Jefferson University
Collaborating Sponsors:
Medtronic
Conditions:
Myocardiopathies
Ischemia, Myocardial
Eligibility:
All Genders
18+ years
Brief Summary
Assess whether serum levels of MMP 2 and or MMP 9 correlate with episodes of ventricular tachycardia or fibrillation in patients who have implantable cardioverter defibrillator devices.
Detailed Description
Sudden cardiac death (SCD) is responsible for 300,000-450,000 deaths per year in the United States. While it is well known that patients with both ischemic and non-ischemic cardiomyopathy (ICM, NICM) ...
Eligibility Criteria
Inclusion
- LVEF of ≤ 35% measured within 6 months of ICD implantation
- NYHA class II-IV at the time of ICD implantation
- ICD implantation at least 1 year prior to enrollment
Exclusion
- Status post heart transplant
- Known malignancy in the past 2 years.
- Recent procedure, intervention or surgery within the past 90 days
- Acute MI, CABG, or PTCA/stent within the past 2 months.
- Active rheumatoid arthritis or pulmonary or hepatic fibrosis.
- Taking chronic steroid therapy for a medical condition
- Currently pregnant
- Enrolled in a concurrent study that may confound the results of this study
Key Trial Info
Start Date :
September 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
63 Patients enrolled
Trial Details
Trial ID
NCT00376532
Start Date
September 1 2006
End Date
September 1 2008
Last Update
June 4 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Jefferson Heart Institute
Philadelphia, Pennsylvania, United States, 19107